Target: CD2.
Clone: LO-CD2a.
Specificity: Anti-CD2 antibody (clone LO-CD2a) activity is directed against human CD2.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: CD2 is expressed on all mature human T cells, most thymocytes, NK cells and a small proportion of bone marrow cells.
Background: LO-CD2a strongly inhibits mixed lymphocyte culture (MLC) 3 and induces T cell apoptosis. Additionally, LO-CD2a does not induce proliferation of resting T cells, and inhibits T cell proliferation induced by OKT3 antibody, induces very low levels of cytokine release, and also inhibits cytokine production induced by OKT3, LO-CD2a strongly inhibits proliferation of peripheral blood mononuclear cells stimulated with soluble OKT3, and induces human T cell hyporesponsiveness. Adding LO-CD2a to a primary MLC inhibits the T cell proliferation response and has a subsequent inhibitory effect on the secondary immune response, thereby blocking primary and memory alloantigen proliferative responses. The human T cell hyporesponsiveness in the secondary MLC is restricted to alloantigens and occurs both in the absence of antibody and after cell surface re-expression of CD2.
Immunogen: LO-CD2a was developed as an immunosuppressive agent for use in organ allotransplantation. LO-CD2a was produced by immunizing a LOU/C rat with purified human T lymphocytes and fusing the splenocytes with the non-secreting rat fusion cell line IR983F, resulting in a rat IgG2b mAb of the IgK-1a allotype.
Concentration: ≥ 2.0 mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >95% by SDS-PAGE.
Endotoxin: <1.0 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 5%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
